HLA-A and colorectal carcinoma: Interestingly, a clinical study screened circulating miRNA biomarkers in the plasma of patients with metastatic CRC treated with HLA‐A*2402 peptide vaccine revealed that miR‐6826 was overexpressed in patients with poor prognosis and metastasis.87